An Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of PUL-042 Inhalation Solution in Subjects With Hematologic Malignancies and Recipients of Stem Cell Transplantation
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2018
At a glance
- Drugs ODN/Pam2 (Primary)
- Indications Pneumocystis pneumonia
- Focus Therapeutic Use
- Sponsors Pulmotect
- 14 Aug 2018 Planned End Date changed from 1 Nov 2019 to 1 Mar 2020.
- 14 Aug 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.
- 14 Aug 2018 Status changed from not yet recruiting to recruiting.